Objectives-To elucidate the potential role of cytokines in the pathogenesis of cardiomyopathy and myocarditis. Background-Experimental studies show that certain cytokines depress myocardial contractility and that tumour necrosis factor-a plays an important part in the pathogenesis of myocardial injury in animal models of viral and autoimmune myocarditis. Methods-Plasma interleukin 1-a, interleukin I-fl, interleukin-2, interleukin-6, tumour necrosis factor-a, tumour necrosis factor-fl, granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, macrophage colony stimulating factor, interferon-a and interferon-y were measured in 13 patients with acute myocarditis, 23 patients with dilated cardiomyopathy, 51 patients with hypertrophic cardiomyopathy, nine patients with acute myocardial infarction, 18 patients with angina pectoris, 12 patients with essential hypertension and 17 healthy controls. Results-Increased concentrations of cytokines were not detected in the controls. In patients with acute myocarditis, interleukin 1-a was detected in 23% (mean (SD) 25 (11) pglml), interleukin l-pl in 31% (56 (34) pglml), tumour necrosis factor-a in 46% (61 (31) pglml), and macrophage colony stimulating factor was 2-5 (1X8) nglml (normal 1*9 (0*4)). In patients with dilated cardiomyopathy, tumour necrosis factor-a was detected in 35% (402 (555) (Br HeartJ_ 1994;72:561-566) 
patients with dilated cardiomyopathy, tumour necrosis factor-a was detected in 35% (402 (555) pglml). In patients with hypertrophic cardiomyopathy, interleukin-2 was detectable in 14% (2318 (4738) pglml) and tumour necrosis factor-a was detected in 20% (992 (1517) pg/ml). The concentration of macrophage colony stimulating factor was raised in patients with acute myocardial infarction. Granulocyte colony stimulating factor was often increased in myocarditis, cardiomyopathies, acute myocardial infarction, and angina pectoris-suggesting activation ofmacrophages and/or endothelial cells-but this increase was not specific to these diseases. Increased concentrations of cytokines were not found in patients with essential hypertension.
Conclusion-These results suggest that
cytokines may play a part in the pathogenesis of myocardial injury in myocarditis and cardiomyopathies and that further studies to explore the potential pathogenetic role of cytokines in myocardial diseases may be warranted. (Br HeartJ_ 1994; 72:561-566) Cytokines are being increasingly recognised as essential mediators of normal and pathological immune responses. It is widely accepted that cytokines are involved in the cascade of events that lead to the wide range of biological responses to exogenous and endogenous pathogens.
A raised concentration of tumour necrosis factor-a has been reported in some patients with acute myocardial infarction.
I Patients with chronic heart failure were also found to have high concentrations of tumour necrosis factor-a, but some cachectic patients did not.23 Tumour necrosis factor-a is also reported to depress myocardial contractility, alter muscle membrane potential, lower blood pressure, and precipitate pulmonary oedema.s6
A recent experimental study showed the importance of interleukin-1 and tumour necrosis factor-a in the pathogenesis of acute viral and autoimmune myocarditis.78 In a study of viral myocarditis in mice, circulating tumour necrosis factor-a was raised in the acute stage, and exogenously administered tumour necrosis factor-a exacerbated the myocarditis. Anti-tumour necrosis factor-a antibody prevented the development of myocarditis. This experimental evidence suggests that tumour necrosis factor-a may play an important part in the pathogenesis of myocardial injury in viral and autoimmune myocarditis. However Interleukin-la, interleukin-i1f, interleukin-2, interleukin-6, tumour necrosis factor-a, tumour necrosis factor-fl, granulocytemacrophage colony stimulating factor, granulocyte colony stimulating factor, interferon-a, and interferon-y were measured by enzyme linked immunoadsorbent assay. Macrophage colony stimulating factor was measured by radioimmunoassay. Cytokines were measured with commercial kits and kits originally developed by the Otsuka Pharmaceutical Company, Tokushima, Japan, according to the manufacturer's protocols. The sensitivity of the kits for each cytokine was 10 pg/ml for interleukin-la, 20 pg/ml for interleukin-l/l, 78 pg/ml for interleukin-2, 32 pg/ml for interleukin-6, 20 pg/ml for tumour necrosis factor-a, 1 U/ml for tumour necrosis factor-fl, 20 pg/ml for granulocyte-macrophage colony stimulating factor, 10 pg/ml for granulocytemacrophage colony stimulating factor, 0-2 ng/ml for macrophage colony stimulating factor, 100 pg/ml for interferon-a, and 10 pg/ml for interferon-y. Samples were run in duplicate, and to calculate the cytokine concentrations recombiant standards were inoculated on every plate. These kits detect natural cytokines and are not affected by the presence of soluble receptors. Results are given as mean (1SD).
DATA ANALYSIS
Frequencies of positive plasma in patients and controls were compared by a x2 test. Data on macrophage colony stimulating factor were compared by an analysis of variance. The clinical variables in patients with detectable or undetectable tumour necrosis factor-a were compared by Student's t test. The correlation between clinical variables in each group of patients with cytokine concentration was analysed by linear regression.
Results

INTERLEUKINS
In the controls interleukin-la, interleukin-1if, interleukin-2, interleukin-6, tumour necrosis factor-a, tumour necrosis factor-fl, granulocyte colony stimulating factor, interferon-a, and interferon-y were below the threshold of detection of our method and macrophage colony stimulating factor was 1 9 (04) ng/ml (mean (1SD)). Interleukin-la was detected in plasma from three (23-1%) of 13 (25 (11) pg/ml) patients with acute myocarditis, in 1 (4 3%) of 23 (14 pg/ml) patients with dilated cardiomyopathy, and 4 (7 8%) of 51 (38 (15) pg/ml) patients with hypertrophic cardiomyopathy ( was very high (> 1000 pg/ml) in four patients with hypertrophic cardiomyopathy. Nonetheless tumour necrosis factor-a was not increased in five patients with hypertrophic cardiomyopathy in whom a dilated ventricle and poor systolic function developed.
COLONY STIMULATING FACTORS
Tumour necrosis factor-fl or granulocytemacrophage colony stimulating factor was detected in only a few of these patients. Granulocyte colony stimulating factor was commonly increased in patients with myocarditis or cardiomyopathy, but no significant differences in frequency were found between the various groups. Raised concentrations of granulocyte colony stimulating factor were not correlated with numbers of leucocytes (data not shown). Macrophage colony stimulating factor in normal volunteers was 1 9 (04) ng/ml. Plasma concentrations of macrophage colony- stimulating factor were 2-5 (1 8) ng/ml in patients with acute myocarditis, 1-5 (0 4) ng/ml in patients with dilated cardiomyopathy, 1 9 (08) ng/ml in patients with hypertrophic cardiomyopathy, (1-1) ng/ml in patients with acute myocardial infarction, 2-4 (0 9) ng/ml in patients with angina pectoris and 1-4 (04) ng/ml in patients with essential hypertension. The concentration of macrophage colony stimulating factor was significantly higher in patients with acute myocarditis and acute myocardial infarction than in those with dilated cardiomyopathy, and the increase was most prominent in those with acute myocardial infarction. Granulocyte-macrophage colony stimulating factor, interferon-a, or interferon-y was uncommonly detected.
Thus, concentrations of inflammatory cytokines such as interleukin-la, interleukin-1B, and tumour necrosis factor-a were increased in patients with acute myocarditis. In addition, tumour necrosis factor-a was increased in patients with dilated cardiomyopathy and hypertrophic cardiomyopathy.
Discussion
Cytokines can be measured in plasma by sensitive and specific immunoradiometric and immunoenzymatic assays. Interleukin-I is a potent cytokine with broad proinflammatory activities.10 Like tumour necrosis factor, it is thought to play a central part in stimulating immune and inflammatory processes in response to microbial infection and tissue injury. Although most of the activities of interleukin-1 appear to favour tissue repair, when it is produced in high concentrations it can upset normal homoeostasis and exacerbate tissue injury." Interleukin-2 hypersecretion is a primary autosomal dominant trait that predisposes to the development of organ-specific autoimmunity."2"3 In our study interleukin-2 was more commonly found in increased concentration in patients with hypertrophic cardiomyopathy. This difference was not statistically significant.
TUMOUR NECROSIS FACTOR-a AND THE HEART
The concentration of tumour necrosis factor-a was reported to be raised in five of 22 patients with acute myocardial infarction and these patients had large infarcts complicated by hypotension and pulmonary oedema.' In our study, however, a raised concentration of tumour necrosis factor-a was uncommon in patients with acute myocardial infarction. When the patients with or without raised concentrations of tumour necrosis factor-a in each group were compared with respect to body weight, blood pressure, heart rate, serum C-reactive protein, serum creatine kinase, glutamic oxaloacetic transaminase, blood urea nitrogen, echocardiographic variables, pulmonary capillary wedge pressure, left ventricular end diastolic pressure, and cardiac index, no significant differences were found (data not shown). Tumour necrosis factor-a has been reported to depress myocardial contractility, alter muscle membrane potential, lower blood pressure, and precipitate pulmonary oedema.F6 Repeated infusions of tumour necrosis factor can lead to a permanent decrease in myocardial contractility and ultimately dilated cardiomyopathy.14
IMPORTANCE OF CYTOKINES IN THE PATHOGENESIS OF MYOCARDITIS
A recent experimental study showed that administration of interleukin-I or tumour necrosis factor-a promoted coxsackievirus B3 myocarditis in genetically resistant B 1OA mice.7 In an experimental model of myocarditis caused by the encephalomyocarditis virus in mice, exogenously administered recombinant human tumour necrosis factor-a increased the virus concentration in the myocardium, produced myocardial necrosis and cellular infiltration, and exacerbated myocarditis. When antibody to tumour necrosis factor a antibody was given survival and myocardial lesions improved.8 In this model, circulating tumour necrosis factor-a was increased in the acute stage8 and antiheart antibody was found in the serum, suggesting that autoimmunity may cause myocardial dysfunction.'5 Antibody against tumour necrosis factor-a also had a beneficial effect in myosininduced autoimmune myocarditis.'6 Evidence from these studies suggests that tumour necrosis factor-a may play an important part in the pathogenesis of myocardial injury in viral and autoimmune myocarditis. In addition to the animal models, a recent study showed that coxsackievirus B3 induced production of tumour necrosis factor-a, interleukin-lfl, and interleukin-6 in human monocytes in vitro. '7 In our study, increased circulating interleukin-1 a, interleukin-lfl, interleukin-6, and tumour necrosis factor-a, the so-called inflammatory cytokines, were found in some patients with acute myocarditis. Various agents cause acute myocarditis but the most important cause is virus infection. Tumour necrosis factor-a is sometimes increased in patients with dilated cardiomyopathy, though less frequently. The most important cause of dilated cardiomyopathy is now believed to be viral myocarditis. ' 
CYTOKINES DEPRESS MYOCARDIAL CONTRACTILITY
Tumour necrosis factor-a, interleukin-6, and interleukin-2 inhibited the contractility of isolated hamster papillary muscles in a concentration-dependent, reversible manner. The nitric oxide synthase inhibitor, NGmonomethyl-L-arginine, blocked these negative inotropic effects. L-Arginine reversed the inhibition by NG-monomethyl-L-arginine. These findings show that the direct negative inotropic effect of cytokines is mediated through a myocardial nitric oxide synthase.3
The contractile response of cultured rat ventricular myocytes to a ,B adrenergic agonist was depressed by a soluble inflammatory mediator produced by induction of an autocrine nitric oxide signalling pathway.2627 The regulation of pro-inflammatory cytokines and myocardial nitric oxide synthase may provide new therapeutic strategies for the treatment of cardiac diseases. In vitro work showed that tumour necrosis factor-a (150-3200 U/ml) had a detrimental cardiovascular effect.25 Because tumour necrosis factor-a has a biological activity of 20-50 U/pg, the concentrations of these cytokines detected in patients seem to be high enough to produce a biological effect.
TUMOUR NECROSIS FACTOR-a AND MAJOR HISTOCOMPATIBILITY COMPLEX
The genes encoding tumour necrosis factor-a and tumour necrosis factor-# are situated within the major histocompatibility complex locus. Familial hypertrophic cardiomyopathy has been shown to be associated with HLA-DR4 and with other major histocompatibility complex haplotypes.28 29 Dilated cardiomyopathy too was reported to be associated with HLA-DR4 and HLA-DQw4.3°Thus, raised concentrations of plasma tumour necrosis factor-a in patients with hypertrophic and dilated cardiomyopathy may be associated with a major histocompatibility complex.
Molecular genetic studies showed that mutations within the fi cardiac myosin heavy chain gene cause hypertrophic cardiomyopathy in some families. ' activation of macrophages and/or endothelial cells; none the less the increase was not specific to the diseases. Although the healthy volunteers were significantly younger than all other groups of patients except for those with myocarditis, the patients with essential hypertension, being older, serve as an appropriate control for the patients with myocardial disease. Macrophage colony stimulating factor is also produced by various cell types, including T cell,'35 and can be elaborated by macrophages or monocytes during adherence and differentiation. Macrophage colony stimulating factor can also induce several other cytokines including interleukin-1 and granulocyte colony stimulating factor and thus upregulate its own synthesis. In this study the increased concentration of macrophage colony stimulating factor in acute myocarditis and acute myocardial infarction may reflect acute damage of cardiac myocytes.
Raised concentrations of plasma cytokines in selected patients may be the consequence of (a) ongoing immune reaction perpetuating a primary cardiac injury; (b) a general response to cardiac injury of other cause; (c) immune activation resulting from systemic circulatory disturbances such as tissue hypoxia or congestion; or (d) the consequence of neuroendocrine responses to cardiac dysfunction such as sympathetic activation or activation of other neuroendocrine pathways. Further studies are necessary to clarify the pathophysiological role of the cytokines in myocardial disease.
CONCLUSIONS
Plasma concentrations of interleukin-1 a, interleuldn-fli, and tumour necrosis factor-a were increased in patients with acute myocarditis. Tumour necrosis factor-a was also increased in dilated cardiomyopathy and hypertrophic cardiomyopathy. These results suggest that cytokines may play an important part in the pathogenesis of myocardial injury in cardiomyopathy and myocarditis and that the potential pathogenetic role of cytokines in myocardial diseases should be explored in further studies.
